HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY

Cover Page


Cite item

Full Text

Abstract

Hypertrophic cardiomyopathy (HCMP) is a relatively common disease with genetic predisposition, that is widely spread irrespective of gender, race or ethnicity. The cause of this pathology are mutations of genes encoding synthesis of contracting proteins. Degree and type of mutations define clinical manifestation of the disease and its prognosis. HCMP is classified according to four main criteria: depending on morphology, presence of left ventricular outlet obstruction, pressure gradient and hemodynamic parameters. Its prevalence amounts to 1:500, and in the recent years mortality has decreased significantly to 1%. Main symptoms of HCMP include dyspnoea, dizziness, syncope, angina, and heart arrhythmias. HCMP does not manifest obligatorily with all above mentioned signs and symptoms. Presence and severity of any symptoms depend on morphological particulars of the disease. Particular attention should be paid to arrhythmias, with atrial fibrillation among them, that may cause hazardous and occasionally lethal complications. Electrocardiography and echocardiography are recognized as the “golden standard” of HCMP diagnostics, while in the recent years, magnetic resonance imaging has become a highly informative diagnostic tool. Radionuclide diagnostics is used less frequently, while physical examination and assessments have been moving backwards. At present, main strategies in HCMP include medical treatment with β-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors and anti-arrhythmics. There are two techniques for surgical treatment, i.e. myectomy by Morrow and alcohol septal ablation that is becoming increasingly popular. The article reviews literature on state-of-the-art diagnostics and treatment of HCMP patients.

About the authors

A. G. Osiev

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: osiev_ag@mail.ru

MD, PhD, Professor, Head of Department of Cardiovascular Surgery

Россия

R. A. Naydenov

Novosibirsk Scientific Research Institute of Blood Circulation Pathology named after E.N. Meshalkin

Email: najden@bk.ru

Doctor, Specialist in Radioendovascular Diagnostics and Treatment of the Center for Interventional Cardiology

Россия

E. I. Kretov

Novosibirsk Scientific Research Institute of Blood Circulation Pathology named after E.N. Meshalkin

Email: fake@neicon.ru

PhD, Leading Research Fellow, a Doctor Specialist in Radioendovascular Diagnostics and Treatment of the Center for Interventional Cardiology

Россия

N. R. Obedinskaya

Novosibirsk Scientific Research Institute of Blood Circulation Pathology named after E.N. Meshalkin

Email: fake@neicon.ru

Doctor, Department of X-ray and Computer Tomography

Россия

V. P. Kurbatov

Novosibirsk Scientific Research Institute of Blood Circulation Pathology named after E.N. Meshalkin

Email: fake@neicon.ru

PhD, Head of Department of X-ray and Computer Tomography

Россия

References

  1. Караськов АМ, Осиев АГ. Гипертрофическая кардиомиопатия с обструкцией выходного отдела левого желудочка. Новосибирск: Дизайн науки; 2012. 187 с. Karas'kov AM, Osiev AG. Gipertroficheskaya kardiomiopatiya s obstruktsiey vykhodnogo otdela levogo zheludochka [Hypertrophic cardiomyopathy with left ventricular outlet obstruction]. Novosibirsk: Dizayn nauki; 2012. 187 p. (in Russian).
  2. Бокерия ЛА, Борисов КВ, Синев АФ, Черникова НА, Злочевская ЕВ. Хирургическая коррекция гипертрофической обструктивной кардиомиопатии у детей при помощи оригинального способа. Грудная и сердечно-сосудистая хирургия. 2003;(2):22–8. Bokeriya LA, Borisov KV, Sinev AF, Chernikova NA, Zlochevskaya EV. Khirurgicheskaya korrektsiya gipertroficheskoy obstruktivnoy kardiomiopatii u detey pri pomoshchi original'nogo sposoba [Surgical correction of hypertrophic obstructive cardiomyopathy in children: an original method]. Grudnaya i serdechno-sosudistaya khirurgiya [Thoracic and Cardiovascular Surgery]. 2003;(2):22–8 (in Russian).
  3. Gruver EJ, Fatkin D, Dodds GA, Kisslo J, Maron BJ, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J Cardiol. 1999;83(12A):13H–18H.
  4. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(25):2703–38.
  5. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.
  6. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287(10): 1308–20.
  7. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242–55..
  8. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295–303.
  9. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–9.
  10. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517–24.
  11. Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation. 2007;116(23):2702–8.
  12. Maron MS, Zenovich AG, Casey SA, Link MS, Udelson JE, Aeppli DM, Maron BJ. Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. Am J Cardiol. 2005;95(11):1329–33.
  13. Bonow RO, Frederick TM, Bacharach SL, Green MV, Goose PW, Maron BJ, Rosing DR. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. Am J Cardiol. 1983;51(8):1386–91.
  14. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol. 1987;60(1):123–9.
  15. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis.Br Heart J. 1981;46(2):168–72.
  16. Skinner JR, Manzoor A, Hayes AM, Joffe HS, Martin RP. A regional study of presentation and outcome of hypertrophic cardiomyopathy in infants. Heart. 1997;77(3):229–33.
  17. Houston BA, Stevens Gerin R. Hypertrophic cardiomyopathy: a review. Clin Med Insights Cardiol. 2014;8(Suppl 1):53–65.
  18. Ghosh S, Avari JN, Rhee EK, Woodard PK, Rudy Y. Hypertrophic cardiomyopathy with preexcitation: insights from noninvasive electrocardiographic imaging (ECGI) and catheter mapping. J Cardiovasc Electrophysiol. 2008;19(11):1215–7.
  19. Абдулаев РЯ, Соболь ЮС, Шиллер НБ, Фостер Э. Современная эхокардиография.Харьков: Фортуна-Пресс; 1998. 240 с. Abdulaev RYa, Sobol' YuS, Shiller NB, Foster E. Sovremennaya ekhokardiografiya [Modern echocardiography]. Kharkov: Fortuna-Press; 1998. 240 p. (in Russian).
  20. Габрусенко СА, Сафрыгина ЮВ, Наумов ВГ, Беленков ЮН. Современные подходы к лечению больных гипертрофической кардиомиопатией. Лечащий врач. 2004;(2):32–7. Gabrusenko SA, Safrygina YuV, Naumov VG, Belenkov YuN. Sovremennye podkhody k lecheniyu bol'nykh gipertroficheskoy kardiomiopatiey [Modern approaches to treatment of patients with hypertrophic cardiomyopathy]. Lechashchiy vrach. 2004;(2):32–7 (in Russian).
  21. Ларина ОМ. Диагностическое значение магнитно-резонансной томографии при гипертрофии миокарда левого желудочка различного генеза. Литературный обзор. Вестник РНЦР. 2010;(10). Доступно на: http://vestnik.rncrr.ru/vestnik/v10/papers/larina_v10.htm Larina OM. Diagnosticheskoe znachenie magnitnorezonansnoy tomografii pri gipertrofii miokarda levogo zheludochka razlichnogo geneza. Literaturnyy obzor [Diagnostic significance of magnetic resonance imaging in left ventricular hypertrophy of various causes. Literature review]. Vestnik RNCRR. 2010;(10). Available from: http://vestnik.rncrr.ru/vestnik/v10/papers/larina_v10.htm (in Russian).
  22. Синицын ВЕ, Стукалова ОВ, Ларина ОВ, Смирнова МД, Агеев ФТ, Терновой СК. Магнитно-резонансная томография сердца с отсроченным контрастированием в оценке очаговых изменений в миокарде левого желудочка у больных с гипертрофической кардиомиопатией. Кардиологический вестник. 2008;(2):54–7. Sinitsyn VE, Stukalova OV, Larina OV, Smirnova MD, Ageev FT, Ternovoy SK. Magnitno-rezonansnaya tomografiya serdtsa s otsrochennym kontrastirovaniem v otsenke ochagovykh izmeneniy v miokarde levogo zheludochka u bol'nykh s gipertroficheskoy kardiomiopatiey [Magnetic resonance imaging
  23. of the heart with delayed contrast filling for assessment of focal lesion of left ventricular myocardium in patients with hypertrophic cardiomyopathy]. Kardiologicheskiy vestnik. 2008;(2):54–7.
  24. Bogaert J, Goldstein M, Tannouri F, Golzarian J, Dymarkowski S. Original report. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. AJR Am J Roentgenol. 2003;180(4):981–5.
  25. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, Petrou M, Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43(12):2260–4.
  26. Keng FY, Chang SM, Cwajg E, He ZX, Lakkis NM, Nagueh SF, Spencer WH 3rd, Verani MS. Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation. J Nucl Cardiol. 2002;9(6):594–600.
  27. Jiang TY, Wu XS, Han ZH, Jia CQ, Mi HZ, Gao YC, Zhang XL. Myocardial condition after transcoronary ablation predicts the curative effect in patients with hypertrophic obstructive cardiomyopathy. Chin Med J (Engl). 2006;119(3):246–9.
  28. Veselka J, Prochazkova S, Duchonova R, Bolomova-Homolova I, Palenickova J, Tesar D, Cervinka P, Honek T. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: Lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv. 2004;63(2):231–5.
  29. Spoladore R, Maron MS, D'Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J. 2012;33(14):1724–33.
  30. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med. 1982;307(16):997–9.
  31. Pollick C, Kimball B, Henderson M, Wigle ED. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol. 1988;62(17):1248–51.
  32. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. Multicenter study of the efficacy and safet of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol.2005;45(8):1251–8.
  33. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian AJ. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103(6):789–91.
  34. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, DeFreitas G, Entman M, Carabello BA, Roberts R, Marian AJ. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109(10):1284–91.
  35. Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy – pathology and pathogenesis. Histopathology. 1995;26(6):493–500.
  36. Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH 3rd, Nagueh SF. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;37(1):208–14.
  37. Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol. 1994;73(8):577–80.
  38. Brock R. Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis. Guys Hosp Rep. 1957;106(4):221–38.
  39. Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaorticventriculomyotomy. Ann Surg. 1961;154:181–9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Osiev A.G., Naydenov R.A., Kretov E.I., Obedinskaya N.R., Kurbatov V.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies